ARTICLE | Product Development
Oral peptide win for Protagonist/J&J, Beam’s base editor POC, and more: Clinical Report
Protagonist data led to week’s biggest share price gain, while Arvinas saw biggest loss: in BioCentury’s latest Clinical Report
March 12, 2025 12:13 AM UTC
The past seven days saw three data disclosures that brought biotech share price gains of at least 40%, while Arvinas sank 51% on proof-of-concept from its lead PROTAC candidate.
The week’s top gainer was Protagonist Therapeutics Inc. (NASDAQ:PTGX), which reported updates from its oral peptide IL-23R antagonist in both psoriasis and ulcerative colitis. In the Phase IIb ANTHEM-UC study, the highest dose of icotrokinra led to a 63.5% response rate — a level rarely seen in ulcerative colitis studies — compared with 27% in the placebo arm. About 30% of patients achieved clinical remission at 12 weeks vs. 11.1% of controls...